Dr. Ying Ge is a Professor in the Department of Cell and Regenerative Biology and Department of Chemistry at University of Wisconsin-Madison. She received a B.S. from Peking University and a Ph.D. from Cornell University under the joint supervision of Prof. Fred McLafferty and Prof. Tadhg Begley. After graduate school, Dr. Ge explored a career in pharmaceutical industry. In 2012, Dr. Ge started her tenure-track Assistant Professor position, received tenure in 2015, and was promoted to Full Professor in 2019. Ge’s research is highly interdisciplinary that cuts across the traditional boundaries of chemistry, biology, and medicine. It is her belief that to make significant impact in molecular medicine, it is necessary to combine technology with function and bridge the silos between basic and translational/clinical research for precision medicine. Dr. Ge has devoted her past twenty years to developing and applying top-down mass spectrometry-based proteomics to biomedical research. Recently her lab has developed a multi-pronged approach to address the challenges in top-down proteomics. Dr. Ge has published over 150 papers with many in high impact journals. She has received a number of awards such as the ASMS Biemann Medal (2020), HUPO Clinical and Translational Proteomics Award (2021), and HPLC Society Georges Guiochon Faculty Fellowship (2016), as well as The Top 100 Analytical Scientist Power List (on a global scale, 2019, 2020 2021). Dr. Ge is passionate about education and has been mentoring students from chemistry, biology and medicine.

Dr. He is the leading scientist studying proteomics in China. He was the founder of CNHUPO and among the first group of people who founded HUPO in 2001. He was the first Chinese scientist who led an international consortium-Human Liver Proteome Project (HLPP), and the founder of Beijing Proteome Research Center, Phoenix Center (proteomics) and Institutes of Biomedical Sciences Fudan University. As the chief scientist, he has been propelling HLPP to the China Human Proteome Project (CNHPP), to create an encyclopedia of proteins in the human body under physiological and pathological conditions. In 2019, his team stratified early hepatocarcinoma (HCC) into 3 proteomic subtypes with different clinical outcome. Some drug targetable proteins have been demonstrated useful in identifying patients with HCC who could potentially benefit from targeted treatment in further clinical trials. These studies demonstrated the proteomic analysis as an independent powerful tool in cancer molecular subtyping, indicating that the era of “Proteomics Driven Precision Medicine (PDPM)” is coming. He is currently proposing a world-wide project called π-HuB (The Proteomic Navigator of the Human Body). It aims at playing a central and catalytic role in biomedical research over the next several decades and providing an ultimate solution at the molecular level for health and well-being of the humankind.

Benjamin A. Garcia obtained his BS in Chemistry at UC Davis in 2000, and then received his PhD in Chemistry in 2005 at the University of Virginia under Prof. Donald Hunt and then was an NIH NRSA Postdoctoral Fellow at the University of Illinois under Prof. Neil Kelleher from 2005-2008. From there Ben was appointed as an Assistant Professor in the Molecular Biology Department at Princeton University from 2008-2012, until his recruitment as the Presidential Associate Professor of Biochemistry and Biophysics at the University of Pennsylvania Perelman School of Medicine in 2012, promoted to full Professor in 2016, and named the John McCrea Dickson M.D. Presidential Professor in 2017. Ben moved in the summer of 2021 to the Washington University School of Medicine in St. Louis to become the Chair of the Department of Biochemistry and Molecular Biophysics. The Garcia lab has been developing and applying novel proteomic approaches and bioinformatics for interrogating protein modifications, especially those involved in epigenetic mechanisms such as histones during human disease, publishing over 350 publications. Ben has also been recognized with many honors and awards for his mass spectrometry research including The ASMS Biemann Medal and was named a Fellow of the Royal Society of Chemistry.

Anne-Claude Gingras is the Canada Research Chair in Functional Proteomics, the Lea Reichmann Chair in Cancer Proteomics and a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute, Sinai Health System. A Full Professor in the department of Molecular Genetics at the University of Toronto, she also serves as as deputy editor of Molecular and Cellular Proteomics and as a co-director of the Network Biology Collaborative Centre (a Genome Canada technology platform). Her lab focuses on the study of signalling pathways using systematic approaches and the development of quantitative proteomics technologies. She has developed computational tools that enable better analysis and visualization of proteomics results, and contribute to training the next generation of proteomics researchers. Using the tools that she developed, her group has identified new protein complexes and signaling components that provide a better understanding of perturbations associated with cancer and rare diseases. She also contributed to Canada’s response to the COVID-19 pandemic by developing high-throughput serology assays. Dr. Gingras has published >275 research articles and review articles that have already been cited 47K times.

Dr. Melvin Park is Director of Research at Bruker Daltonics. He received his bachelor’s degrees in Chemistry and Physics from NC State University in 1986 and a Ph.D. in Chemistry from Texas A&M in 1991. His dissertation centered on secondary ion mass spectrometry, coincidence counting, and time-of-flight mass spectrometry, and their application to surface analysis. After postdoctoral studies at the Naval Research Laboratories in 1993 regarding MALDI TOF, he joined Bruker. Over the past nearly three decades he and his colleagues have produced more than 80 issued patents and 30 peer reviewed journal articles in all areas of mass spectrometry and, more recently, ion mobility spectrometry. The most well-known of these is trapped ion mobility spectrometry (TIMS). His current work is the continued advancement and application of mass spectrometry, TIMS, and their peripherals.

Glycoinformatics researcher since 2003, responsible for the glycan repository GlyTouCan, the glycomics MS repositories GlycoPOST (raw data) and UniCarb-DR (glycans), which are all accessible from the glycoscience Web portal GlyCosmos.

Jean Armengaud is specialized in mass spectrometry for biology and more specifically in proteogenomics and metaproteomics. He manages the ProGénoMIX platform located near Avignon in France. He wishes to contribute to a better understanding of the functioning of complex biological systems and exploit this knowledge for medical and environmental purposes. He received his PhD in Biochemistry in 1994 at the University of Grenoble.

Since 2019 Ben is a Reader (equiv. Assoc. Prof.) in the the School of Biological Sciences, Queen’s University of Belfast, UK. His research focuses on broadly on 3 topics: (i) method development and applications in data independent acquisition mass spectrometry; (ii) method development and applications in the analysis of protein interaction networks and protein complexes; and (iii) applications of these strategies in host-pathogen biology and innate immunity. Ben’s PhD was completed at University College Dublin in 2009 where he remained for 1 year as the Agilent Technologies Newman Fellow (postdoctoral) in Quantitative Proteomics. Ben moved to the Institute of Molecular Systems Biology at ETH Zurich in Autumn 2010 as postdoctoral researcher under the supervision of Prof. Ruedi Aebersold, where his research focused on the application of quantitative interaction proteomics in signaling and the development of DIA/SWATH mass spectrometry. Following this Ben was a Group Leader and SNF Ambizione Fellow at IMSB, ETH Zurich with a focus on applying methods developed as a postdoc to relevant problems in host-pathogen biology.

Michael Angelo, MD PhD is a board-certified pathologist in the department of Pathology at Stanford University School of Medicine. Dr. Angelo is a leader in high dimensional imaging with expertise in tissue homeostasis, tumor immunology, and infectious disease. His lab has pioneered the construction and development of Multiplexed Ion Beam Imaging by time of flight (MIBI-TOF). MIBI-TOF uses secondary ion mass spectrometry and metal-tagged antibodies to achieve rapid, simultaneous imaging of dozens of proteins at subcellular resolution. His lab has used this novel technology to discover previously unknown rule sets governing the spatial organization and cellular composition of immune and stromal cells within the tumor microenvironment in triple negative breast cancer and ductal carcinoma in situ. This effort has led to ongoing work aimed to define broader structural mechanisms that promote tolerogenic niches in cancer, tuberculosis, and the maternal fetal interface. Dr. Angelo is the recipient of 2014 NIH Director’s Early Independence, 2020 DOD Era of Hope Award and is a principal investigator on multiple extramural awards from the National Cancer Institute, Breast Cancer Research Foundation, Parker Institute for Cancer Immunotherapy, the Bill and Melinda Gates Foundation, and the Human Biomolecular Atlas (HuBMAP) initiative.

I am an Assistant Professor at Cedars-Sinai Heart Institute, with a broad background of biochemistry, molecular biology, immunology, and proteomics to study organ function and regulation in health and disease. My research involves inter-institutional collaborations focused on identifying novel and/or largely understudied biologic markers of heart failure (HF) with the major role of proteins posttranslational modifications (PTMs). I am pioneer in the understanding of arginine deiminases, enzymes family that introduce PTM, called citrullination and their contributions to many processes, like aging, inflammation, and their link with disease development and progression. Uncovering these biological bases are long term goals of my lab expanding to other physiological or pathological conditions. In fact, the COVID-19 pandemic experience has profoundly impact research at my lab and our work has been focuses on i) sex and race differences in both susceptibility and response to SARS-CoV-2 exposure and response to SARS-COV-2 infection; ii) sex and race differences in both positive and negative response to SARS-CoV-2 vaccine, and iii) linking adaptive immune response – autoimmunity with Long COVID, post-acute sequelae of SARS-CoV-2 infection. The concept of profiling autoantibodies in healthy and disease patients combined with multi-omic data will form the basis of disease prediction allowing for earlier intervention linked to disease prevention strategies, as well as earlier, effective and personalized interventions for established disease.

Dr. Jennifer Geddes-McAlister started her appointment as Assistant Professor in the Department of Molecular and Cellular Biology at the University of Guelph in July 2018. She is an expert in mass spectrometry-based proteomics following a Alexander von Humboldt post-doctoral fellowship at the Max Planck Institute of Biochemistry (Germany). Her research program aims to define the relationship between host and pathogen during infection to uncover new strategies for overcoming resistance in both medically- and agriculturally-relevant diseases. Dr. Geddes-McAlister is the elected Vice President, Communications and Board member for the Canadian National Proteomics Network (CNPN), co-Founder of the Canadian Proteomics and Artificial Intelligence Research and Training Consortium (CanProAI), and the elected Western Hemisphere Diversity Candidate for the Human Proteome Organization (HUPO). She recently founded ‘Moms in Proteomics’, an initiative dedicated to mentoring and supporting mothers in STEM and foudnded the CNPN Unity initiative to promote equity, diversity, and inclusion in proteomics research and training across Canada.